Safe neoadjuvant trastuzumab-based treatment in HER2 + inflammatory early breast cancer in a glucose 6-phosphate dehydrogenase-deficient postmenopausal woman: A case report and review of the literature.
Alberto Jacobo Cunquero-TomásClaudio D Ávila-AndradeJavier MilaraKarla JavierVega IranzoCarlos CampsPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)
Although the role of HER2 and trastuzumab in oxidative stress is not yet completely understood, we suggest that trastuzumab may be a suitable agent for treatment in patients with HER2-enriched breast cancer in a non-oxidative chemotherapy scheme, with acceptable responses and no triggering hemolytic crisis.
Keyphrases
- oxidative stress
- epidermal growth factor receptor
- early breast cancer
- metastatic breast cancer
- public health
- lymph node
- dna damage
- type diabetes
- skeletal muscle
- radiation therapy
- metabolic syndrome
- young adults
- combination therapy
- blood pressure
- ischemia reperfusion injury
- induced apoptosis
- blood glucose
- endoplasmic reticulum stress
- signaling pathway
- case report
- heat shock